Table 2.
Details of medically managed patients
| 1st visit | MDT clinic | Final follow up | p | |
|---|---|---|---|---|
| n | 132 | 132 | 116 | |
| Drug (%) | <0.001 | |||
| No drugs | 4 (3.0) | 18 (13.6) | 25 (21.6) | |
| Monotherapy | 102 (77.3) | 81 (61.4) | 70 (60.3) | |
| Polytherapy | 26 (19.7) | 33 (25.0) | 21 (18.1) | |
| CBZ (%) | 54 (40.9) | 31 (23.5) | 22 (19.0) | <0.001 |
| OXC (%) | 56 (42.4) | 61 (46.2) | 49 (42.2) | 0.769 |
| GAB (%) | 8 (6.1) | 6 (4.5) | 4 (3.4) | 0.622 |
| LAM (%) | 16 (12.1) | 32 (24.2) | 26 (22.4) | 0.050 |
| PHE (%) | 0 (0) | 0 (0) | 0 (0) | NA |
| BAC (%) | 5 (3.8) | 2 (1.5) | 2 (1.7) | 0.412 |
| LID (%) | 2 (1.5) | 2 (1.5) | 5 (4.3) | 0.256 |
| Other drug (%) | 14 (10.6) | 15 (11.4) | 116 (100.0) | <0.001 |
| Pain (%) | <0.001 | |||
| Pain free off drugs | 0 (0.0) | 18 (15.5) | ||
| Pain free with drugs | 6 (4.5) | 10 (8.6) | ||
| Mild pain | 14 (10.6) | 50 (43.1) | ||
| Moderate pain | 19 (14.4) | 25 (21.6) | ||
| Severe pain | 93 (70.5) | 13 (11.2) |
CBZ Carbamazepine, OXC Oxcarbazepine, GAB Gabapentin, LAM Lamotrigine, PHE Phenytoin, BAC Baclofen, LID Lidocaine